Skip to main content
. 2017 Dec 8;9(4):4661–4674. doi: 10.18632/oncotarget.23163

Figure 1.

Figure 1

Vehicle or sunitinib treatment in control (A) sensitive (B) and resistant (CD) xenograft groups. Arrows show treatment start points. Mice were sacrified at the time points indicated by stars [*]. Sunitinib treatment resulted in stability of tumor volume for 3 weeks (no tumor regrowth) compared to control group. Resistance started to develop after four weeks of treatment and tumors grew rapidly after 6-7 weeks.